Beijing,February 29,2025 – A new diabetes drug,mazdutide,is showing promise as a more effective tool for both blood sugar control and weight loss compared to existing treatments. The findings, released today, suggest a potential shift in how type 2 diabetes is managed, moving beyond simply lowering glucose to actively tackling obesity-a major driver of the disease.
Mazdutide combines two types of hormones to address diabetes from multiple angles.
- Mazdutide, a once-weekly injection, demonstrated superior HbA1c reduction compared to dulaglutide.
- Participants on mazdutide experienced greater weight loss-approximately 4-6% more than those on dulaglutide.
- the drug was generally well-tolerated, with gastrointestinal side effects being the most common.
- The trial was conducted on a Chinese population with type 2 diabetes, and further research is needed in diverse groups.
Q: How much better is mazdutide at lowering blood sugar? A: In a 28-week trial, mazdutide reduced HbA1c by approximately 0.25-0.30 percentage points more than dulaglutide, a commonly prescribed diabetes medication, suggesting a clinically meaningful improvement.
Mazdutide Demonstrates Superior Glycemic Control
The phase 3 trial, published in Nature, enrolled 731 adults with type 2 diabetes already managing their condition with oral medications. Participants were randomly assigned to recieve either mazdutide or dulaglutide, a GLP-1 receptor agonist, for 28 weeks.The results showed that mazdutide led to significantly greater reductions in HbA1c, a key measure of long-term blood sugar control, compared to dulaglutide.
Furthermore, participants treated with mazdutide experienced more significant weight loss, averaging approximately 4-6% greater reduction in body weight than those receiving dulaglutide. This added benefit is especially significant, as obesity often exacerbates type 2 diabetes and contributes to cardiovascular risk.
During the 28-week study period, mazdutide was generally well-tolerated. As with other incretin-based therapies, gastrointestinal side effects-specifically diarrhea, nausea, and vomiting-were reported more frequently with mazdutide than with dulaglutide.However, no serious safety concerns were identified during the trial.
Context and Future Directions
This research was conducted on a population of Chinese adults with type 2 diabetes. While the results are encouraging, further studies are needed to confirm these findings in more diverse populations. The trial demonstrates that mazdutide can achieve greater improvements in both glycemic control and body weight compared to an established GLP-1 receptor agonist. The findings suggest dual-agonist therapies could play an increasingly important role in diabetes management, though their immediate clinical impact requires further inquiry.
Reference
Guo L et al; DREAMS-2 investigators. Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes.Nature. 2025; DOI:10.1038/s41586-025-10031-z.
